Genomic Medicine: How Whole Genome Sequencing Is Transforming Healthcare
Genomic medicine — the application of genomic information to clinical decision-making — has moved from specialised research centres to mainstream healthcare with remarkable speed. What was a theoretical possibility in the early 2000s is now clinical reality: whole genome sequencing is being used to diagnose rare diseases that eluded traditional testing, guide cancer treatment decisions, screen newborns for treatable conditions, and inform medication choices based on individual genetic profiles. The transformation of healthcare by genomics is underway, and its pace continues to accelerate.
Rare Disease Diagnosis: The Clearest Clinical Win
Rare diseases — conditions affecting fewer than 1 in 2,000 people — collectively affect an estimated 300 million people worldwide, and the majority have genetic causes. Historically, patients with rare genetic conditions often endured years of diagnostic odyssey, seeing multiple specialists and undergoing numerous inconclusive tests before receiving a diagnosis, if they received one at all. WGS has dramatically shortened this journey for many patients. By examining the entire genome in a single test, WGS can identify variants that cause rare diseases even when the specific condition was not suspected in advance. Health systems in the UK, Australia, and several other countries now offer WGS as a routine diagnostic tool for suspected rare disease, and diagnostic rates in this context typically reach 25% to 40% — substantially higher than previous genetic testing approaches.
Cancer Genomics: Precision Oncology
Cancer is fundamentally a genomic disease — it arises when somatic mutations accumulate in cells and drive uncontrolled growth. Comprehensive tumour sequencing, typically comparing the genome of a patient's tumour to their germline (non-tumour) genome, identifies the specific mutations driving a particular cancer, determines whether those mutations are targetable by existing drugs, and reveals prognostic information about likely disease behaviour. Precision oncology — matching treatments to tumour genomic profiles — has produced dramatic results in some cancers: targeted therapies against specific EGFR mutations in lung cancer, ALK fusions in lung cancer, BRCA mutations in breast and ovarian cancer, and BRAF mutations in melanoma have transformed outcomes for patients whose tumours carry these alterations.
Pharmacogenomics in Clinical Practice
Pharmacogenomics — the study of how genetic variation affects drug response — is one of the most immediately actionable areas of genomic medicine. Variants in genes encoding drug-metabolising enzymes (particularly the cytochrome P450 family), drug transporters, and drug targets predict which patients will respond normally to standard doses, which will metabolise a drug too quickly to achieve therapeutic levels, and which face increased risk of adverse reactions. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides clinical prescribing guidelines for dozens of gene-drug pairs, and pharmacogenomic testing is increasingly embedded in clinical workflows for conditions including cardiovascular disease, oncology, psychiatry, and pain management.
Newborn Genomic Screening
Newborn screening programmes currently test for a panel of treatable metabolic and other conditions using a blood spot taken at birth. Genomic newborn screening — sequencing the complete or near-complete genome of every newborn — is the subject of active clinical research and pilot programmes in several countries. Proponents argue that comprehensive genomic screening could identify hundreds of treatable conditions not covered by current panels, enabling earlier intervention. Critics raise concerns about the implications of identifying disease-predisposing variants for conditions that may not manifest until adulthood, the management of incidental findings, and the equity of implementation. These debates reflect the broader challenge of integrating powerful genomic tools thoughtfully and equitably into healthcare systems.
Learn more about genomic medicine and clinical sequencing on our genomics healthcare resources hub, or contact us for information about WGS applications in clinical settings.